Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-elamipretide-for-barth-syndrome-treatment-302242393.html

PR NEWSWIRE
09 Sep 2024

https://www.prnewswire.com/news-releases/stealth-biotherapeutics-completes-mid-cycle-review-meeting-on-elamipretide-for-the-treatment-of-barth-syndrome-302207846.html

PR NEWSWIRE
29 Jul 2024

https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-first-patient-enrolled-in-global-phase-3-clinical-program-for-elamipretide-in-patients-with-dry-age-related-macular-degeneration-302164947.html

PR NEWSWIRE
05 Jun 2024

https://www.prnewswire.com/news-releases/stealth-biotherapeutics-barth-syndrome-nda-receives-priority-review-designation-302138192.html

PR NEWSWIRE
07 May 2024

https://endpts.com/stealth-bio-gets-fda-adcomm-for-previously-rejected-ultra-rare-disease-drug/

Zachary Brennan ENDPTS
09 Apr 2024

https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome-302109608.html

PR NEWSWIRE
08 Apr 2024